China's So-Young Q2 revenue rises, net loss narrows
SY•Analyst coverage
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell".
The average consensus recommendation for the miscellaneous specialty retailers peer group is "buy".
Wall Street's median 12-month price target for So-Young International Inc is $7.30, about 204.2% above its August 28 closing price of $2.40.
Quarterly results
China aesthetic treatment platform So-Young said second-quarter revenue rose 33% year over year, driven by branded center expansion.
The company said the net loss for the quarter narrowed year over year, reflecting improved operational efficiency.
| Metric | Actual |
|---|---|
| Q2 Revenue | RMB 505.23 mln |
| Q2 Net Loss | RMB 22.70 mln |
| Q2 Gross Profit | RMB 222.85 mln |
| Q2 Income from Operations | -RMB 43.63 mln |
| Q2 Operating Expenses | RMB 266.48 mln |
| Q2 Pretax Loss | RMB 27.15 mln |
Outlook and operating drivers
So-Young expects third-quarter 2026 aesthetic treatment services revenue of RMB 352 mln to RMB 362 mln.
The company plans to accelerate AI-powered transformation and strengthen supply chain, and said it sees a clear path toward profitability as economies of scale continue to unfold.
Result drivers
